Assessment of Abuse Potential of Rapastinel in Humans

Summary

Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.

Timeline

Start

2018-11-01

Primary completion

2019-03-24

Completion

2019-03-29

Drugs

Indications